Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.
Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.
On April 4, 2023, Novavax, Inc. (Nasdaq: NVAX) announced its participation in the World Vaccine Congress (WVC) and the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The company will showcase data on its COVID-19 prototype vaccine as a booster and its COVID-Influenza Combination (CIC) vaccine. Key presentations include insights on vaccine hesitancy and safety surveillance, scheduled from April 3 to 6 in Washington, DC, and April 15 to 18 in Copenhagen, Denmark. Novavax is also a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards in two categories, with winners announced on April 4.
Novavax (Nasdaq: NVAX), a leader in protein-based vaccines, announced its participation in the TD Cowen's 43rd Annual Health Care Conference on March 8, 2023, from 9:50 – 10:20 a.m. EST. The conference will take place at the Boston Marriott Copley Place. John Trizzino, Chief Commercial Officer, will represent the company during a fireside chat moderated by Georgi Yordanov, an Equity Research Analyst in Biotechnology. A replay of the session will be accessible on Novavax's website for 90 days post-conference.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
